The stock of Rocket Pharmaceuticals Inc (RCKT) has seen a 0.32% increase in the past week, with a 20.11% gain in the past month, and a -35.93% decrease in the past quarter. The volatility ratio for the week is 10.90%, and the volatility levels for the past 30 days are at 8.99% for RCKT. The simple moving average for the past 20 days is -10.28% for RCKT’s stock, with a -52.39% simple moving average for the past 200 days.
Is It Worth Investing in Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Right Now?
RCKT has 36-month beta value of 0.92. Analysts have mixed views on the stock, with 12 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RCKT is 99.95M, and currently, short sellers hold a 12.26% ratio of that float. The average trading volume of RCKT on May 13, 2025 was 2.62M shares.
RCKT) stock’s latest price update
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has seen a decline in its stock price by -9.57 in relation to its previous close of 7.00. However, the company has experienced a 0.32% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-05-09 that CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the company will be presenting data for the first time from the Phase 1 clinical trial of RP-A601 to treat patients with plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM) at the Annual Meeting of the American Society of Gene and Cell Thera.
Analysts’ Opinion of RCKT
Many brokerage firms have already submitted their reports for RCKT stocks, with BMO Capital Markets repeating the rating for RCKT by listing it as a “Outperform.” The predicted price for RCKT in the upcoming period, according to BMO Capital Markets is $50 based on the research report published on March 12, 2025 of the current year 2025.
Wedbush, on the other hand, stated in their research note that they expect to see RCKT reach a price target of $32. The rating they have provided for RCKT stocks is “Outperform” according to the report published on December 30th, 2024.
Jefferies gave a rating of “Buy” to RCKT, setting the target price at $29 in the report published on December 18th of the previous year.
RCKT Trading at -12.81% from the 50-Day Moving Average
After a stumble in the market that brought RCKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.54% of loss for the given period.
Volatility was left at 8.99%, however, over the last 30 days, the volatility rate increased by 10.90%, as shares surge +8.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.08% lower at present.
During the last 5 trading sessions, RCKT rose by +1.58%, which changed the moving average for the period of 200-days by -75.23% in comparison to the 20-day moving average, which settled at $7.06. In addition, Rocket Pharmaceuticals Inc saw -49.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RCKT starting from Militello John, who sale 718 shares at the price of $7.16 back on Apr 22 ’25. After this action, Militello John now owns 65,039 shares of Rocket Pharmaceuticals Inc, valued at $5,139 using the latest closing price.
Militello John, the Officer of Rocket Pharmaceuticals Inc, proposed sale 718 shares at $7.16 during a trade that took place back on Apr 22 ’25, which means that Militello John is holding shares at $5,140 based on the most recent closing price.
Stock Fundamentals for RCKT
The total capital return value is set at -0.56. Equity return is now at value -60.45, with -53.17 for asset returns.
Based on Rocket Pharmaceuticals Inc (RCKT), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -8.23. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -144.86.
Currently, EBITDA for the company is -273.2 million with net debt to EBITDA at 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.19.
Conclusion
To put it simply, Rocket Pharmaceuticals Inc (RCKT) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
